{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"SMAD4 encodes a tumor suppressor and transcription factor that is a downstream effector in the TGF-\u00df signal transduction pathway. SMAD4 is frequently mutated in pancreatic and colorectal cancer and infrequently mutated in various other cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"04/07/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "26488212"
      ]
    },
    "description":"The SMAD4 E330K mutation is located in the MH2 domain, which is an interaction surface for SMAD4 binding partners. Expression of this mutation in HT-29 cell lines resulted in decreased SMAD-mediated transcription, likely leading to altered TGF\u00df -mediated growth control (PMID: 26488212).",
    "knownEffect":"Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"E330K",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":4089,
    "hgvs":"18:g.51065455G>A",
    "hugoSymbol":"SMAD4",
    "id":null,
    "proteinEnd":330,
    "proteinStart":330,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The SMAD4 E330K mutation is likely oncogenic.",
  "vus":false
}